Cited by 428Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

Subjective cognitive decline and rates of incident Alzheimer's disease and non-Alzheimer's disease dementia

Open access
Slot, Rosalinde E.R., Sikkes, Sietske A.M., Berkhof, Johannes, Brodaty, Henry, Buckley, Rachel, Cavedo, Enrica, Dardiotis, Efthimios, Guillo‐Benarous, Francoise +27 more·2019·Alzheimer's & Dementia

Abstract

INTRODUCTION: In this multicenter study on subjective cognitive decline (SCD) in community-based and memory clinic settings, we assessed the (1) incidence of Alzheimer's disease (AD) and non-AD dementia and (2) determinants of progression to dementia. METHODS: Eleven cohorts provided 2978 participants with SCD and 1391 controls. We estimated dementia incidence and identified risk factors using Cox proportional hazards models. RESULTS: In SCD, incidence of dementia was 17.7 (95% Poisson confidence interval 15.2-20.3)/1000 person-years (AD: 11.5 [9.6-13.7], non-AD: 6.1 [4.7-7.7]), compared with 14.2 (11.3-17.6) in controls (AD: 10.1 [7.7-13.0], non-AD: 4.1 [2.6-6.0]). The risk of dementia was strongly increased in SCD in a memory clinic setting but less so in a community-based setting. In addition, higher age (hazard ratio 1.1 [95% confidence interval 1.1-1.1]), lower Mini-Mental State Examination (0.7 [0.66-0.8]), and apolipoprotein E ε4 (1.8 [1.3-2.5]) increased the risk of dementia. DISCUSSION: SCD can precede both AD and non-AD dementia. Despite their younger age, individuals with SCD in a memory clinic setting have a higher risk of dementia than those in community-based cohorts.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jalz.2018.10.003

Cites

61 of 61 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • SCD is associated with increased risks of AD biomarker abnormalities and future cognitive decline and dementia.

    “SCD is postulated to manifest at a relatively late phase of preclinical AD and is associated with increased risks of AD biomarker abnormalities and future cognitive decline and dementia [2, 4, 6]”

    From Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease (2020) · cites this paper as [6]

    The Introduction (page unavailable) states that people with SCD have an increased risk of subsequent objective cognitive decline and dementia, and the Results report higher dementia incidence in SCD than in controls, especially in memory-clinic cohorts. The paper does not establish an increased risk of AD biomarker abnormalities; the Discussion says biomarker data were unavailable for a large part of the cohort. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • SCD is postulated to manifest at a relatively late phase of preclinical AD.

    “SCD is postulated to manifest at a relatively late phase of preclinical AD and is associated with increased risks of AD biomarker abnormalities and future cognitive decline and dementia [2, 4, 6]”
  • Subjective cognitive decline might be a risk factor of clinical progression, but the ability of subjective cognitive decline to predict progression to objective cognitive decline remains low (OR 1·5-3·08).

    “Subjective cognitive decline might be a risk factor of clinical progression,24 but the ability of subjective cognitive decline to predict progression to objective cognitive decline (ie, mild cognitive decline, or dementia, or both) remains low (OR 1·5–3·081).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Slot, R. E. R., Sikkes, S. A. M., Berkhof, J., Brodaty, H., Buckley, R., Cavedo, E., Dardiotis, E., Guillo‐Benarous, F., Hampel, H., Kochan, N. A., Lista, S., Luck, T., Maruff, P., Molinuevo, J. L., Kornhuber, J., Reisberg, B., Riedel‐Heller, S. G., Risacher, S. L., Roehr, S., Sachdev, P. S., Scarmeas, N., Scheltens, P., Shulman, M. B., Saykin, A. J., Verfaillie, S. C. J., Visser, P. J., Vos, S. J. B., Wagner, M., Wolfsgruber, S., Jessen, F., Initiative, T. A. D. N., the DESCRIPA working group, the INSIGHT‐preAD study group, SCD‐I working group, & van der Flier, W. M.
Affiliations
  • Amsterdam Neuroscience (NL)
  • Amsterdam University Medical Centers (NL)
  • UNSW Sydney (AU)
  • Harvard University (US)
  • Centre National de la Recherche Scientifique (FR)
  • University of Thessaly (GR)
  • NYU Langone Health (US)
  • Nordhausen University of Applied Sciences (DE)
  • Florey Institute of Neuroscience and Mental Health (AU)
  • Neurology Department Hospital Clínic i Universitari‐IDIBAPS and BarcelonaBeta Brain Research Center Pasqual Maragall Foundation Barcelona Spain
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
  • Institute of Social Medicine Occupational Health and Public Health (ISAP) Faculty of Medicine University of Leipzig Leipzig Germany
  • Indiana University Indianapolis (US)
  • National and Kapodistrian University of Athens (GR)
  • Maastricht University (NL)
  • University of Bonn (DE)
  • University of Cologne (DE)
  • Alzheimer Center Amsterdam Department of Neurology Amsterdam Neuroscience Vrije Universiteit Amsterdam Amsterdam UMC Amsterdam the Netherlands
Corresponding author
the Alzheimer's Disease Neuroimaging Initiative
Venue
Alzheimer's & Dementia
Publisher
Wiley
Published
2018-12-13
Volume
15
Issue
3
Pages
465-476
ISSN
  • 1552-5260 (ISSN-L)
  • 1552-5279
OpenAlex
W2904079367
Cited by
428
References
61
Citations by year
2026: 39 · 2025: 55 · 2024: 68 · 2023: 65 · 2022: 65 · 2021: 54 · 2020: 62 · 2019: 17 · 2018: 3
FWCI
26.57
Type
journal article
Language
en
Open access
Locations
  • Alzheimer s & Dementia (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion, cc-by)
  • VU Research Portal (publishedVersion, other-oa)
  • Europe PMC (PubMed Central) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (acceptedVersion, cc-by-nc-nd)
  • Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
  • HAL (submittedVersion, cc-by-nc-nd)
  • Research Publications (Maastricht University) (submittedVersion, cc-by-nc-nd)
  • University of Thessaly Institutional Repository (University of Thessaly) (submittedVersion)
  • CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion, other-oa)
  • Massey Research Online (Massey University) (submittedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (submittedVersion, other-oa)
  • IUScholarWorks (Indiana University) (submittedVersion)
  • Purdue University Indianapolis (Indiana University) (submittedVersion)
  • Research Publications (Maastricht University) (submittedVersion, other-oa)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
Funders
  • ZonMw
  • Alzheimer's Association (IIRG-09-133014)
  • Centre Hospitalier Universitaire de Bordeaux (CIC EC7)
  • AXA Research Fund
  • U.S. Department of Health and Human Services (AG08051, AG03051)
  • National Institute on Aging (P30 AG010133, R01 AG019771, K01 AG049050)
  • U.S. Department of Defense (W81XWH-12-2-0012)
  • National Institute of Biomedical Imaging and Bioengineering
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cancer-related cognitive impairment studies
Keywords
subjective cognitive decline, Alzheimer's disease
MeSH terms
Aged, Aged, 80 and over, Dementia, Female, Humans, Male, Middle Aged, Risk Factors, Self Concept, Cohort Studies, Incidence, Disease Progression, Diagnostic Self Evaluation, Cognitive Dysfunction

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review